NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.05 -0.17 (-0.23%) GOLD FUTURES
2,370.50 +1.20 (+0.05%) DOW
38,571.03 -115.29 (-0.30%) Bitcoin GBP
53,707.46 +820.61 (+1.55%)
REGN Jun 2024 725.000 put
| Previous close | 2.6800 |
| Open | 3.5000 |
| Bid | 0.0000 |
| Ask | 4.6000 |
| Strike | 725.00 |
| Expiry date | 2024-06-21 |
| Day's range | 2.6800 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Insider MonkeyIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is the best bet in the gene therapy sector. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
BenzingaFDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
On Friday, the FDA extended the target action date of priority review of supplemental application seeking approval for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD), a lung disease that’s usually caused by smoking. The revised target action date is September 27, 2024. The FDA accepted the application in February, with a target action date of June 27, 2024. The FDA did not raise any concerns regardi
ZacksFDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
